Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Symphogen/Meiji antibody progress triggers milestone

This article was originally published in Scrip

Executive Summary

Meiji Seikahas begun the preclinical development of Sym006, a recombinant polyclonal antibody discovered by Symphogentargeting an undisclosed bacterial pathogen. The move triggers a milestone payment to the private Danish firm as part of a basic research collaboration signed two years ago. Under this, Symphogen is applying its antibody discovery, manufacturing and characterisation technology in return for milestones, sales royalties and other project funding from Meiji. It also has an option to co-develop Sym006 in the US and Europe after the completion of the first Phase II trial, in which case profits would be shared equally. The polyclonal antibodies are derived from human B lymphocytes against target antigens and mimic the natural immune response.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008002

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel